2025-10-23 - Analysis Report
Okay, here's an analysis of Hims & Hers Health Inc. (HIMS) based on the data provided, presented in English with simplified numbers and analysis:

**0. Report Summary**

This report provides an analysis of Hims & Hers Health Inc. (HIMS) stock, comparing its performance against the S&P 500 (VOO), examining recent price movements and indicators, analyzing news and analyst opinions, and reviewing recent earnings and financial information.  The overall conclusion is nuanced, with positive growth trends offset by some concerning analyst ratings and insider activity.

**1. Performance vs. S&P 500 (VOO)**

*   **Ticker:** HIMS
*   **Company:** Hims & Hers Health Inc. (A multi-specialty telehealth company focused on providing personalized health and wellness experiences to consumers.)
*   **HIMS Cumulative Return:** 223.7%
*   **VOO Cumulative Return:** 73.0%
*   **Deviation:**
    *   Max: 321.5
    *   Min: -86.1
    *   Current: 154.1
    *   Relative Deviation: 58.9

**Analysis:** HIMS has significantly outperformed the S&P 500 over the observed period. The relative deviation of 58.9 indicates that HIMS is currently positioned in the upper half of its historical performance range relative to the S&P 500. The high relative deviation may suggest the stock is overbought or priced optimistically.

**Alpha, Beta Analysis Table:**

| Year        | CAGR      | MDD   | Alpha   | Beta  | Cap(B) |
| ----------- | --------- | ----- | ------- | ----- | ------ |
| 2019-2021   | -42.0%    | 74.4% | -81.0%  | 0.0   | 1.4    |
| 2020-2022   | -19.0%    | 78.6% | -18.0%  | -0.0  | 1.4    |
| 2021-2023   | -65.0%    | 78.6% | -67.0%  | -0.1  | 1.9    |
| 2022-2024   | 119.0%   | 79.4% | 98.0%   | -0.0  | 5.3    |
| 2023-2025   | 228.0%   | 80.8% | 165.0%  | 0.1   | 10.8   |

**Analysis:**

*   **CAGR:** The Compound Annual Growth Rate shows a significant improvement, turning sharply positive in the most recent periods (2022-2024 and 2023-2025).
*   **MDD:** The Maximum Drawdown is consistently high, indicating significant volatility and potential for large price declines.
*   **Alpha:** Alpha measures the stock's performance relative to the market. The recent positive alpha (98.0% and 165.0%) indicates HIMS has been significantly outperforming the market on a risk-adjusted basis.
*   **Beta:** Beta is close to zero, suggesting that HIMS's price is not highly correlated with the overall market.
*   **Cap(B):** The market capitalization has been growing significantly, showing increasing investor confidence and company expansion.

**2. Recent Price Action**

*   **Current Price:** $49.36
*   **Last Market Data:** Price: $47.46, Previous Close: $49.36, Change: -3.85%
*   **5-Day Moving Average:** $54.48
*   **20-Day Moving Average:** $55.41
*   **60-Day Moving Average:** $52.21

**Analysis:** The stock price is below all three moving averages, suggesting a short-term downtrend.  The last market data indicates a significant single-day price drop (-3.85%), which could be a reaction to recent news or events.

**3. Indicators & Signals**

*   **Market Risk Indicator (MRI):** 0.9 (Medium Investment)
*   **RSI:** 42.02 (Neutral, not yet oversold)
*   **PPO:** -1.73 (Negative, indicating short-term weakness)
*   **Hybrid Signal:** Cash_0%_Buy 100% of cash (17 shares - Very Safe - MRI:0.90)
*   **20-Day Relative Deviation Change:** -7.9 (Short-term decline)
*   **Expected Return:** 4.3% (Long-term outperformance vs. S&P 500 if investing consistently)

**Analysis:** The MRI suggests a medium investment recommendation. RSI and PPO are neutral to slightly negative, aligning with the short-term downtrend indicated by the price action. The recent negative change in relative deviation reinforces this short-term weakness.  The hybrid signal suggests a buying opportunity, perhaps based on the MRI reading and long-term potential. The 4.3% expected return is a positive factor for long-term investors. The significant price change of -3.85% likely impacted these indicators.

**4. Recent News & Significant Events**

*   **Positive:**
    *   Hims & Hers Advances AI-Powered Personalized Digital Healthcare
    *   Could Hims & Hers Health's (HIMS) Menopause Expansion Reveal a New Competitive Edge in Women's Care?
    *   HIMS Stock Declines Despite Launch of New Specialty in Women's Health
*   **Negative/Neutral:**
    *   KeyBanc starts Hims & Hers with caution on margin
    *   CEO Andrew Dudum Is Ditching Hims & Hers Stock.
    *   Goldman downgraded, Coinbase initiated: Wall Street's top analyst calls (Indirectly relevant, reflects general market sentiment)

**Analysis:**  The news is mixed.  Positive developments include advancements in AI and expansion into women's health. However, concerns about margins and the CEO selling shares are potential red flags. The market's negative reaction to the launch of a new specialty in women's health is also concerning.

**4-2. Analyst Opinions**

*   **Consensus:** Hold
*   **Mean Rating:** 2.93 (Hold)
*   **Number of Opinions:** 13
*   **Target Price:**
    *   Average: $47.77
    *   High: $85.00
    *   Low: $25.00

**Analysis:** The analyst consensus is "Hold," with a relatively wide range in target prices, suggesting uncertainty about the stock's future. The average target price is slightly below the current price, indicating potential downside.

**5. Recent Earnings Analysis**

| Date       | EPS  | Revenue      |
| ---------- | ---- | ------------- |
| 2025-08-04 | 0.19 | 0.54 B$      |
| 2025-05-05 | 0.22 | 0.59 B$      |
| 2024-11-04 | 0.35 | 0.40 B$      |
| 2024-08-05 | 0.06 | 0.32 B$      |
| 2025-08-04 | 0.06 | 0.32 B$      |

**Analysis:** The earnings per share (EPS) and revenue figures show an upward trend over the last few quarters, indicating growth in profitability and sales.

**6. Financial Information**

**Revenue and Profitability:**

| Quarter      | Revenue   | Profit Margin |
| ------------ | --------- | ------------- |
| 2025-06-30   | $0.54B    | 76.39%        |
| 2025-03-31   | $0.59B    | 73.50%        |
| 2024-12-31   | $0.48B    | 76.81%        |
| 2024-09-30   | $0.40B    | 79.16%        |
| 2024-06-30   | $0.32B    | 81.30%        |

**Capital and Profitability:**

| Quarter      | Equity    | ROE       |
| ------------ | --------- | --------- |
| 2025-06-30   | $0.56B    | 7.55%     |
| 2025-03-31   | $0.55B    | 9.01%     |
| 2024-12-31   | $0.48B    | 5.46%     |
| 2024-09-30   | $0.44B    | 17.18%    |
| 2024-06-30   | $0.36B    | 3.67%     |

**Analysis:**

*   **Revenue and Profitability:** The revenue has generally increased over the past quarters, indicating business growth. The profit margin has been relatively stable, suggesting efficient operations.
*   **Capital and Profitability:** The equity has grown, reflecting increasing assets. The Return on Equity (ROE) has fluctuated but generally shows positive profitability.

**7. 종합 Analysis (Overall Analysis)**

*   **Positive:** HIMS has significantly outperformed the S&P 500 in the past. Revenue and EPS are trending upward. The company is expanding into new areas like women's health and leveraging AI. The MRI suggests a "Medium Investment" rating. The hybrid signal suggests a buying opportunity.
*   **Negative:** The stock is in a short-term downtrend, with recent price declines and negative signals from RSI and PPO. Analyst consensus is "Hold," with an average price target below the current price.  The CEO selling shares is a potential concern. High MDD and volatile performance historically. Caution from KeyBanc on margin.
*   **Neutral:** The company's beta is near zero, indicating that its performance is not strongly correlated with the broader market.

**Conclusion:**

HIMS presents a mixed investment picture.  The company demonstrates strong growth potential and has significantly outperformed the market in the past. However, recent price action, analyst sentiment, and insider activity suggest caution.

**Recommendation:**

A cautious approach is warranted.  Investors should carefully consider their risk tolerance and investment horizon. Monitoring future earnings reports, analyst ratings, and news developments is crucial before making a decision. Small, incremental investments might be a reasonable approach for those interested in the company's long-term potential, but avoid large positions until the short-term headwinds clear and analyst sentiment improves.
